lutrate depot 22,5 mg powder and solvent for prolonged - release suspension for injection
csc pharmaceuticals handels gmbh - Лейпрорелин - 22,5 mg powder and solvent for prolonged - release suspension for injection
lutrate depot 3,75 mg powder and solvent for prolonged - release suspension for injection
csc pharmaceuticals handels gmbh - Лейпрорелин - 3,75 mg powder and solvent for prolonged - release suspension for injection
gemcitabine csc 200 mg powder for solution for infusion
gp pharm, s.a. - 200 mg powder for solution for infusion
gemcitabine csc 1 000 mg powder for solution for infusion
gp pharm, s.a. - 1 000 mg powder for solution for infusion
irinotecan csc 20 mg/ml concentrate for solution for infusion
gp pharm, s.a. - 20 mg/ml concentrate for solution for infusion
octreotide csc 500 micrograms/ml solution for injection
gp pharm, s.a. - 500 micrograms/ml solution for injection
octreotide csc 100 micrograms/ml solution for injection
gp pharm, s.a. - 100 micrograms/ml solution for injection
octreotide csc 50 micrograms/ml solution for injection
gp pharm, s.a. - 50 micrograms/ml solution for injection
oxaliplatin csc 5 mg/ml powder for solution for infusion
gp pharm, s.a. - 5 mg/ml powder for solution for infusion
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - Карцином, сквамозна клетка - Антинеопластични средства - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.